Africa: HIV/AIDS
Commons · Question 67364 · Tabled 14 Jul 2025 · Foreign, Commonwealth and Development Office · Official record
Answered 24 Jul 2025
Question
Asked by Wendy Morton
To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, if he will make a comparative assessment of the potential impact of using (a) Lenacapavir, (b) other long-lasting HIV prevention drugs, (c) PrEP and (d) other daily HIV preve
Answer
Answered by Stephen Doughty, 24 Jul 2025
Long-acting technologies could be game-changers in the global response to HIV, but only if they reach the countries and communities that need them most, including young women and girls in sub-Saharan Africa and the most vulnerable and marginalised groups ...